Compare YieldMax AMD Option Income Strategy ETF (AMDY) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax AMD Option Income Strategy ETF vs TG Therapeutics Inc — how do they compare? YieldMax AMD Option Income Strategy ETF trades at $53.45, while TG Therapeutics Inc trades at $55.47 (market cap $8.74B). Which is the better fit depends on your goals.
| AMDY | TGTX | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $59.52 | $59.06 |
52-Week Low | $29.80 | $26.39 |
Market Cap | — | $8.74B |
Enterprise Value | — | $8.98B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMDY trades at $55.56, up 2.04% today, with a bullish technical signal from moving averages and neutral oscillators. The ETF shows strong weekly dividend distributions but lacks traditional valuation metrics. Recent news highlights its high-yield strategy and associated risks of NAV erosion, with support at $54 and resistance at $56.
The outlook is mixed: high income appeals, but structural risks and analyst caution suggest volatility. Investors must weigh yield sustainability against potential capital depreciation, with entry timing critical for long-term viability.
TG Therapeutics (TGTX) trades at $57.12, down 3.28% on the day, amid mixed technical signals. The stock exhibits strong profitability with a net income margin of 65.95% and robust revenue growth, reaching $616.29 million in 2025. Recent positive news includes the initiation of a Phase II trial for Briumvi in schizophrenia and strong sales momentum, though recent quarterly EPS results have missed expectations. The technical outlook is bullish based on moving averages, but oscillators show bearish pressure with RSI levels indicating potential overbought conditions.
The investment outlook for TGTX is supported by strong analyst sentiment with 84.62% buy ratings and a consensus price target of $45.00, though the current price exceeds this target. Key opportunities include pipeline expansion and rising Briumvi demand, but risks involve clinical trial outcomes, competitive pressures, and cash flow volatility. Investors should weigh the high valuation multiples against growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About YieldMax AMD Option Income Strategy ETF
AMDY is an active ETF that seeks to generate weekly income by selling call options on AMD stock. It aims to provide investors with high yield while maintaining exposure to the price movements of Advanced Micro Devices.
Read more on AMDY →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
